Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03429218 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03429218 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 24 participants.
The verdict
NCT03429218, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase, a constitutively active serine/threonine receptor kinase due to activating mutations or upregulated upstream signaling pathways. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-0184 administered once weekly for 4 weeks in patients with advanced solid tumors.
Interventions
- DRUG TP-0184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03429218
The ClinicalTrials.gov registry entry for NCT03429218 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TP-0184 is the first listed.
NCT03429218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03429218 about?
NCT03429218 is a clinical study titled "First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors". TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase, a constitutively active serine/threonine receptor kinase due to activating mutations or upregulated upstream signaling pathways. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose ...
What is the current status of trial NCT03429218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-07-10. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT03429218?
The interventions under investigation include: TP-0184 (DRUG).
Who is sponsoring clinical trial NCT03429218?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.